Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents
|出版日期||內容資訊||英文 144 Pages
|主要已開發國家的老年癡呆症治療藥市場:由於對高齡化人口與疾病的理解改善，疾病修飾劑的需求增加 Alzheimer's Disease Therapeutics in Major Developed Markets to 2021 - Aging Population and Improved Disease Understanding Increase Demand for Disease Modifying Agents|
|出版日期: 2016年02月01日||內容資訊: 英文 144 Pages||
主要8個市場上的老年癡呆症治療藥市場，從2014年的52億美元，2021年增加到113億美元，預計以11.8％的年複合成長率 (CAGR) 成長。
Alzheimer's Disease (AD) is an irreversible, progressive neurodegenerative disease, characterized by cognitive impairment, memory loss and functional decline. Symptoms typically begin to first appear in patients in their mid-sixties, with symptoms appearing in varying stages. The pathological features of AD comprise histopathological changes within the brain. Mild Cognitive Impairment (MCI) is a heterogeneous condition between normal cognition and dementia, whereby cognitive changes in mental abilities, such as memory or thinking, are affected. Almost all cases of AD begin with MCI, but it should be noted that not all patients with MCI go on to develop AD.
Although there is a high degree of failure and uncertainty within the R&D of AD drugs, the number of drugs in the pipeline is considerably high at 559. The majority of the pipeline products are novel drugs, with a total of seven repositioned and five generic drugs. This shows advancement in the progression of the different molecules being developed as therapeutic agents within the AD pipeline.
The AD market has a lack of therapeutic options.
This report will allow you to -